Donald Halbert this week was named executive vice president of research and development for Iconix Pharmaceuticals. Halbert was director of genomics, proteomics, and bioinformatics in the global pharmaceutical research and development group of Abbott Laboratories. Additionally, Halbert directed Abbott's toxicogenomics program and oversaw the scientific advisory committee that directed a collaboration between Abbott and Iconix that was initiated in December 2003. Before joining Abbott, Halbert was an executive with Becton Dickinson.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.